{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:27:45Z","timestamp":1787027265049,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2023 Henan Provincial Medical Science and Technology Program Joint Construction Project","award":["LHGJ20231009"],"award-info":[{"award-number":["LHGJ20231009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13780-y","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:35:04Z","timestamp":1781166904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for tigecycline-associated drug-induced liver injury in critically Ill patients: a 2020\u20132023 retrospective study from a Chinese hospital"],"prefix":"10.1186","volume":"26","author":[{"given":"Yonghui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaozhe","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"13780_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1086\/505494","volume":"43","author":"GE Stein","year":"2006","unstructured":"Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43:518\u201324.","journal-title":"Clin Infect Dis"},{"key":"13780_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2015.06.011","volume":"83","author":"HS Sader","year":"2015","unstructured":"Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010\u20132013). Diagn Microbiol Infect Dis. 2015;83:183\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"13780_CR3","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s10096-019-03673-1","volume":"38","author":"F Hu","year":"2019","unstructured":"Hu F, Guo Y, Yang Y, Zheng Y, Wu S, Jiang X, Zhu D, Wang F. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38:2275\u201381.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"13780_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75:187\u2013212.","journal-title":"Clin Infect Dis"},{"key":"13780_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, de Waele J, Daikos GL, Akova M, Harbarth S, Pulcini C, Garnacho-Montero J, Seme K, Tumbarello M, Lindemann PC, Gandra S, Yu Y, Bassetti M, Mouton JW, Tacconelli E. Rodr\u00edguez-Ba\u00f1o, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28:521\u201347.","journal-title":"Clin Microbiol Infect"},{"key":"13780_CR6","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024.","DOI":"10.1093\/cid\/ciae403"},{"key":"13780_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11096-022-01397-5","volume":"44","author":"C Wei","year":"2022","unstructured":"Wei C, Liu Y, Jiang A, Wu B. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data. Int J Clin Pharm. 2022;44:709\u201316.","journal-title":"Int J Clin Pharm"},{"key":"13780_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/FTD.0000000000000784","volume":"42","author":"G Fan","year":"2020","unstructured":"Fan G, Jin L, Bai H, Jiang K, Xie J, Dong Y. Safety and Efficacy of Tigecycline in Intensive Care Unit Patients Based on Therapeutic Drug Monitoring. Ther Drug Monit. 2020;42:835\u201340.","journal-title":"Ther Drug Monit"},{"key":"13780_CR9","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","volume":"49","author":"J Breedt","year":"2005","unstructured":"Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, Gioud-Paquet M, Dartois N, Ellis-Grosse EJ, Loh E. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49:4658\u201366.","journal-title":"Antimicrob Agents Chemother"},{"key":"13780_CR10","doi-asserted-by":"publisher","first-page":"761167","DOI":"10.3389\/fphar.2021.761167","volume":"12","author":"X Shi","year":"2021","unstructured":"Shi X, Zuo C, Yu L, Lao D, Li X, Xu Q, Lv Q. Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM. Front Pharmacol. 2021;12:761167.","journal-title":"Front Pharmacol"},{"key":"13780_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12879-022-07258-w","volume":"22","author":"X Shi","year":"2022","unstructured":"Shi X, Lao D, Xu Q, Li X, Lv Q. A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale. BMC Infect Dis. 2022;22:368.","journal-title":"BMC Infect Dis"},{"key":"13780_CR12","first-page":"318","volume":"22","author":"D Turan G\u00f6k\u00e7e","year":"2024","unstructured":"Turan G\u00f6k\u00e7e D, Ar\u0131 D, Ayd\u0131n O, Turhan N, Altunsoy A, \u00d6kten RS. Akdo\u011fan Kayhan, Tigecycline-Associated Hepatic Steatosis After Liver Transplant: A Case Report. Exp Clin Transpl. 2024;22:318\u201321.","journal-title":"Exp Clin Transpl"},{"key":"13780_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.diagmicrobio.2008.09.001","volume":"63","author":"C Bergallo","year":"2009","unstructured":"Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63:52\u201361.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"13780_CR14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s00134-014-3323-7","volume":"40","author":"P Montravers","year":"2014","unstructured":"Montravers P, Dupont H, Bedos JP, Bret P. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med. 2014;40:988\u201397.","journal-title":"Intensive Care Med"},{"key":"13780_CR15","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/cc13858","volume":"18","author":"G De Pascale","year":"2014","unstructured":"De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90.","journal-title":"Crit Care"},{"key":"13780_CR16","doi-asserted-by":"publisher","first-page":"300060518760435","DOI":"10.1177\/0300060518760435","volume":"48","author":"S Lin","year":"2020","unstructured":"Lin S, Liang L, Zhang C, Ye S. Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia. J Int Med Res. 2020;48:300060518760435.","journal-title":"J Int Med Res"},{"key":"13780_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/archinternmed.2012.340","volume":"172","author":"T Eguale","year":"2012","unstructured":"Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med. 2012;172:781\u20138.","journal-title":"Arch Intern Med"},{"key":"13780_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12879-018-3103-z","volume":"18","author":"J Lin","year":"2018","unstructured":"Lin J, Wang R, Chen J. Tigecycline-induced acute pancreatitis in a renal transplant patient: a case report and literature review. BMC Infect Dis. 2018;18:201.","journal-title":"BMC Infect Dis"},{"key":"13780_CR19","doi-asserted-by":"publisher","first-page":"e12467","DOI":"10.1097\/MD.0000000000012467","volume":"97","author":"Z Chen","year":"2018","unstructured":"Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Med (Baltim). 2018;97:e12467.","journal-title":"Med (Baltim)"},{"key":"13780_CR20","first-page":"355","volume":"31","author":"[Chinese guideline for diagnosis","year":"2023","unstructured":"[Chinese guideline for diagnosis. and management of drug-induced liver injury (2023 version)]. Zhonghua Gan Zang Bing Za Zhi. 2023;31:355\u201384.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"13780_CR21","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/jcph.2099","volume":"62","author":"T Jiang","year":"2022","unstructured":"Jiang T, Huang X, Liu Q, Feng H, Huang Y, Lin J, Huang L, Chen S, Zhuang Y, Weng C. Risk Factors for Tigecycline-Associated Hepatotoxicity in Patients in the Intensive Care Units of 2 Tertiary Hospitals: A Retrospective Study. J Clin Pharmacol. 2022;62:1426\u201334.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"13780_CR22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(12)60002-6","volume":"56","author":"J Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(1):S1\u201312.","journal-title":"J Hepatol"},{"key":"13780_CR23","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/17425255.2011.623126","volume":"7","author":"H Giamarellou","year":"2011","unstructured":"Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011;7:1459\u201370.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"13780_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.yrtph.2015.05.004","volume":"72","author":"A Suzuki","year":"2015","unstructured":"Suzuki A, Yuen NA, Ilic K, Miller RT, Reese MJ, Brown HR, Ambroso JI, Falls JG, Hunt CM. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase\u2122. Regul Toxicol Pharmacol. 2015;72:481\u201390.","journal-title":"Regul Toxicol Pharmacol"},{"key":"13780_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/FTD.0000000000001115","volume":"45","author":"X Yang","year":"2023","unstructured":"Yang X, Jin L, Luo X, An S, Wang M, Zhu H, Zhou Y, Liu H. Pharmacokinetic\/Pharmacodynamic Target Attainment of Tigecycline in Patients with Hepatic Impairment in a Real-World Setting. Ther Drug Monit. 2023;45:786\u201391.","journal-title":"Ther Drug Monit"},{"key":"13780_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/toxsci\/kfq269","volume":"118","author":"RE Morgan","year":"2010","unstructured":"Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW Jr., Lightfoot-Dunn R, Hamadeh HK. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010;118:485\u2013500.","journal-title":"Toxicol Sci"},{"key":"13780_CR27","doi-asserted-by":"publisher","first-page":"1342947","DOI":"10.3389\/fphar.2024.1342947","volume":"15","author":"W Su","year":"2024","unstructured":"Su W, Song S, Liu J, Yu H, Feng B, Wu Y, Guo F, Yu Z. Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling. Front Pharmacol. 2024;15:1342947.","journal-title":"Front Pharmacol"},{"key":"13780_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5:58.","journal-title":"Nat Rev Dis Primers"},{"key":"13780_CR29","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","volume":"66","author":"GA Kullak-Ublick","year":"2017","unstructured":"Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66:1154\u201364.","journal-title":"Gut"},{"key":"13780_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14787210.2025.2472346","volume":"23","author":"J Guo","year":"2025","unstructured":"Guo J, Cai X, Wang S, Wen H, Ren J, Zhou M, Li X, Yan X, Tian S, Zhang F, Liu Y, Zhang W, Shao Y, Cao J, Liu X, Hou K, Wei D, Lin G. Standard dose could be better! A multicenter study of tigecycline in patients with liver failure. Expert Rev Anti Infect Ther. 2025;23:415\u201323.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"13780_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijid.2022.04.024","volume":"120","author":"Z Yu","year":"2022","unstructured":"Yu Z, Zhao Y, Jin J, Zhu J, Yu L, Han G. Prevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study. Int J Infect Dis. 2022;120:59\u201364.","journal-title":"Int J Infect Dis"},{"key":"13780_CR32","doi-asserted-by":"publisher","first-page":"1512091","DOI":"10.3389\/fmicb.2024.1512091","volume":"15","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Liu G, Tang X, Xia B, Yu Y, Fan G. Prediction and analysis of toxic and side effects of tigecycline based on deep learning. Front Microbiol. 2024;15:1512091.","journal-title":"Front Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13780-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:26:18Z","timestamp":1787023578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13780-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13780"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13780-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9180785\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research has been approved by the Ethics Committee of Zhumadian Central Hospital, with the approval date of February 1st, 2024, and the approval number 2024-02-KY010. This study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all individual participants involved in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1511"}}